FDA grants priority review for Daiichi Sankyo-AstraZeneca’s Enhertu
The US FDA has granted priority review to the sBLA for ENHERTU, a treatment developed by Daiichi Sankyo and AstraZeneca for solid tumours.
The US FDA has granted priority review to the sBLA for ENHERTU, a treatment developed by Daiichi Sankyo and AstraZeneca for solid tumours.
What's Your Reaction?
